Juvelook Volume Near Seoul at Incheon Airport

PDLLA vs. PLLA: Racemic Configuration and Collagen Kinetics

Juvelook Volume utilizes poly-D,L-lactic acid (PDLLA), a racemic mixture of D-lactic acid and L-lactic acid isomers, as opposed to Sculptra’s pure poly-L-lactic acid (PLLA). This racemic configuration has significant clinical implications. PDLLA is amorphous (non-crystalline), which means it degrades more uniformly and predictably than semi-crystalline PLLA. The hydrolysis rate of amorphous PDLLA is faster than crystalline PLLA, leading to earlier onset of fibroblast activation and collagen deposition — typically visible at 4-8 weeks versus 8-12 weeks for PLLA. However, the total duration of biostimulation is comparable because PDLLA microspheres are formulated at larger diameters (150-250 micrometers) that compensate for the faster degradation rate. The clinical result is a biostimulator that begins working sooner while maintaining an 18-24 month result window.

Neocollagenesis Mechanism: From Microsphere to Collagen Scaffold

When PDLLA microspheres are deposited in tissue, the body recognizes them as biocompatible foreign bodies. Macrophages surround each microsphere, releasing cytokines (particularly TGF-beta1 and PDGF) that recruit and activate local fibroblasts. These fibroblasts begin depositing new collagen fibers — initially type III (immature) collagen in a reticular pattern around the microsphere surface. Over weeks to months, collagen remodeling replaces type III with mature type I collagen organized in parallel bundles. The critical insight is that this collagen scaffold persists long after the PDLLA microsphere fully biodegrades — because collagen turnover in the deep dermis is measured in years, not months. Fitzgerald et al. (2018) demonstrated using histological analysis that PLLA-stimulated collagen remained structurally organized at 24 months post-injection even though the polymer was fully absorbed.

Hyaluronic Acid Carrier: Immediate Volume and Tissue Hydration

Juvelook Volume’s cross-linked HA carrier provides immediate volumizing effect through its water-binding capacity — each HA molecule binds up to 1,000 times its weight in water, creating gel volume in the tissue. This addresses a key limitation of pure biostimulators like Sculptra: the 2-3 month waiting period before visible results. The HA carrier also creates an optimal hydrated microenvironment that may enhance fibroblast activity and collagen deposition around the PDLLA microspheres. As the HA gradually degrades over 3-6 months through enzymatic and oxidative pathways, the newly formed collagen seamlessly takes over the volumizing role. RE:BERRY’s combination approach — using HA fillers where instant precision is needed and Juvelook Volume where long-term biostimulation is the goal — leverages the strengths of both technologies.

Safety Profile and Nodule Risk Mitigation

The primary safety concern with any biostimulator is granuloma or nodule formation. PDLLA’s amorphous structure may confer a lower nodule risk compared to semi-crystalline polymers because uniform degradation reduces the likelihood of crystalline residue acting as a persistent foreign body nidus. Clinical series by Kim et al. (2019) reported nodule incidence below 1.5% with PDLLA-based biostimulators when proper technique (blunt cannula, post-injection massage, appropriate depth placement) was followed. At RE:BERRY, Dr. Cho’s protocol includes 5 minutes of post-injection massage per treated area and detailed patient instructions for home massage during the first 5 days — a critical component of nodule prevention.

References: Fitzgerald R et al. Dermatol Surg. 2018;44(Suppl 1):S5-S20. doi:10.1097/DSS.0000000000001686 | Kim JA et al. J Cosmet Dermatol. 2019;18(4):1095-1101. doi:10.1111/jocd.12807 | Vleggaar D, Bauer U. Dermatol Surg. 2004;30(12 Pt 2):1576-1583. doi:10.1111/j.1524-4725.2004.30551.x